高等学校化学学报

• 研究论文 • 上一篇    下一篇

异吲哚啉酮类ERK抑制剂的设计、合成及初步生物活性研究

张灵芝1,鞠秋荣2,管哲3,朱启华2,张婷婷1,杨诗勤1,徐云根2   

  1. 1. 苏州健雄职业技术学院生物医药学院 2. 中国药科大学药物化学系 3. 苏州信达生物制药(苏州)有限公司
  • 收稿日期:2025-04-25 修回日期:2025-06-24 网络首发:2025-06-25 发布日期:2025-06-25
  • 通讯作者: 徐云根
  • 基金资助:
    2023年度省高校基础科学(自然科学)研究项目(批准号:23KJB350008)和2024年度太仓市基础研究计划面上项目(批准号:TC2024JC21)资助

Design, Synthesis and Biological Evaluation of ERK Inhibitors with Isoindolin-1-one Structure

ZHANG Lingzhi1*, JU Qiurong2, GUAN Zhe3, ZHU Qihua2, ZHANG Tingting1, YANG Shiqin1, XU Yungen2   

  1. 1. College of Biopharmacy, Suzhou Chien-Shiung Institute of Technology

    2. Department of Medical Chemistry, China Pharmaceutical University

    3. INNOVENT BIOLOGICS (SUZHOU) CO. LTD.

  • Received:2025-04-25 Revised:2025-06-24 Online First:2025-06-25 Published:2025-06-25
  • Contact: Yungen Xu
  • Supported by:
    Supported by the Natural Science Foundation of the Jiangsu Higher Education Institutions of China (No. 23KJB350008) and Taicang Research Foundation for Basic Research Plan General Project (No. TC2024JC21)

摘要: 本研究以ERK抑制剂EK-I-22和MK-8353为先导化合物,利用药效团融合策略,设计合成了14个异吲哚啉酮类目标化合物。初步的药理活性测试结果显示,化合物19a(IC50 = 16 nM)、19b(IC50 = 15 nM)、19e(IC50 = 20 nM)、30a(IC50 = 19 nM)和30b(IC50 = 56 nM)对ERK2激酶具有较好的抑制活性,其中化合物30b对四种人肿瘤细胞(Colo-205、A375、A2058和HT-29)均具有一定的抑制活性。

关键词: MAPK信号通路, ERK抑制剂, 合成, 抗肿瘤活性

Abstract: Using the ERK inhibitor EK-I-22 and MK-8353 as the lead compounds, 14 compounds were designed and synthesized by pharmacophore fusion strategy. Preliminary pharmacological activity assessments revealed that compounds 19a(16 nM), 19b(15 nM), 19e(20 nM), 30a(19 nM), and 30b(56 nM) exhibited significant inhibitory activity against ERK2 kinase. Notably, compound 30b demonstrated moderate inhibitory effects against four human tumor cell lines (Colo-205, A375, A2058, and HT-29).

Key words: MAPK pathway, ERK inhibitors, Synthesis, Antitumor activity

中图分类号: 

TrendMD: